Yili Chuanning Biotechnology Co. Ltd. A
Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. The company offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deace… Read more
Yili Chuanning Biotechnology Co. Ltd. A (301301) - Total Liabilities
Latest total liabilities as of June 2025: CN¥2.37 Billion CNY
Based on the latest financial reports, Yili Chuanning Biotechnology Co. Ltd. A (301301) has total liabilities worth CN¥2.37 Billion CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Yili Chuanning Biotechnology Co. Ltd. A - Total Liabilities Trend (2021–2024)
This chart illustrates how Yili Chuanning Biotechnology Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Yili Chuanning Biotechnology Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Yili Chuanning Biotechnology Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Energisa S.A
SA:ENGI3
|
Brazil | R$60.22 Billion |
|
Maharashtra Scooters Limited
NSE:MAHSCOOTER
|
India | ₹42.37 Billion |
|
Direcional Engenharia S.A.
SA:DIRR3
|
Brazil | R$9.70 Billion |
|
Synsam AB
ST:SYNSAM
|
Sweden | Skr5.42 Billion |
|
Harbin Electric Coporation Jiamusi Electric Machine Co Ltd
SHE:000922
|
China | CN¥4.54 Billion |
|
Beijing Haitian Ruisheng Science Technology Ltd
SHG:688787
|
China | CN¥116.34 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Yili Chuanning Biotechnology Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Yili Chuanning Biotechnology Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Yili Chuanning Biotechnology Co. Ltd. A (2021–2024)
The table below shows the annual total liabilities of Yili Chuanning Biotechnology Co. Ltd. A from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.64 Billion | -16.69% |
| 2023-12-31 | CN¥3.17 Billion | -24.27% |
| 2022-12-31 | CN¥4.18 Billion | -10.77% |
| 2021-12-31 | CN¥4.68 Billion | -- |